WHO ICTRP trial
Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with…
JPRN-UMIN000005226 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000005226 |
|---|---|
| Public title | Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung cancer |
| Scientific title | Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung cancer - Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung cancer |
| Primary sponsor | School of Medicine, Keio University |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Japan |
| Conditions | advanced or recurrent non-small-cell lung cancer |
| Interventions | Gemcitabine 1,000 mg/m2/day day1,8,15 WT1 peptide days1,15 q4w , 2 cycle |
| Registration date | Oct 3, 2011 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: